文献速递临床试验与 GCP

聚丙烯酸-聚乙烯吡咯烷酮复合物用于血液透析后止血:开放标签交叉随机对照试验研究方案(PAA-PVP研究)

Polyacrylic acid-polyvinylpyrrolidone complex for achieving hemostasis after hemodialysis: study protocol for an open-label crossover randomized controlled trial (PAA-PVP study).
PubMed 文献 · Trials · 2025-05-24

本研究为开放标签交叉随机对照试验,计划纳入50名每周三次血液透析的患者,比较聚丙烯酸-聚乙烯吡咯烷酮(PAA-PVP)复合物与常规无纺布垫在血管通路穿刺点止血的效果。主要终点为血管通路动脉侧止血时间,采用混合效应模型分析。研究将提供PAA-PVP复合物能否缩短止血时间的证据。

要点

  • PAA-PVP复合物吸收血液或消毒液后形成水凝胶并黏附体表,发挥强力止血作用。
  • 采用个体3+3设计,连续三周每周三次止血测试,逐周缩短测试时间点。
  • 主要终点为血管通路动脉侧止血时间,使用混合效应模型分析。

关键数值与推荐

  • 排除标准包括:使用常规垫压迫止血需超过10分钟者,或穿刺血管通路部位有严重皮肤问题者。
  • 止血测试在11、9、7、5、3和1分钟进行,连续三周每周三次。
  • 个体3+3设计:一周三次均止血成功者下周挑战更短时间;三次中两次成功者下周同一时间点测试;仅一次或零次成功则终止研究治疗。
  • 连续三次成功的最短时间记录为止血时间。
  • 主要终点为血管通路动脉侧止血时间,采用混合效应模型分析,协变量包括止血技术、组别、周期和个体效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Achieving rapid and secure hemostasis of the vascular access point is important for patients undergoing maintenance hemodialysis (HD). We developed a polyacrylic acid-polyvinylpyrrolidone (PAA-PVP) complex that absorbs moisture such as blood or sterilizing solution, forms a hydrogel, and adheres to the body's surface, thereby exerting a powerful hemostatic effect. This study aims to compare the effect of PAA-PVP complex versus a conventional non-woven fabric pad on hemostasis at the needle puncture vascular access site in patients on HD. METHODS: This open-label crossover randomized controlled trial will include 50 participants who undergo thrice-weekly HD. Participants in whom hemostasis requires more than 10 min by compression using a conventional pad or who have a severe skin problem at the needle puncture vascular access site will be excluded from the study. Participants will be randomized in a 1:1 ratio to receive either the PAA-PVP complex or conventional pads. Three consecutive weekly hemostatic tests will be performed at 11, 9, 7, 5, 3, and 1 min. The study will employ an individual 3+3 design in which participants in whom hemostasis is achieved in all three sessions in a week will be challenged to a shorter time in the three sessions of the next week. Those in whom hemostasis is achieved in two of three sessions will be tested at the same time point in the three sessions of the next week. The study treatment will be terminated if hemostasis is achieved in only one or none of the sessions, and the minimum time with three consecutive successes will be recorded as the hemostasis time. The primary endpoint, the hemostasis time on the arterial side of the vascular access, will be analyzed using mixed-effect models for repeated measures and include the hemostatic technique and group, period, and individual effects as covariates. DISCUSSION: The study will provide evidence on whether the PAA-PVP complex reduces hemostasis time of the vascular access compared to conventional pad in patients on HD. TRIAL REGISTRATION: jRCTs032220597 (Japan Registry of Clinical Trials; registered on January 30, 2023, https://jrct.niph.go.jp/latest-detail/jRCTs032220597 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Terashima R, Tanaka M, Hashimoto A, et al. Polyacrylic acid-polyvinylpyrrolidone complex for achieving hemostasis after hemodialysis: study protocol for an open-label crossover randomized controlled trial (PAA-PVP study). Trials. 2025. PMID: 40413558. doi:10.1186/s13063-025-08877-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。